JPMorgan Chase & Co. Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

JPMorgan Chase & Co. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 71.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 221,485 shares of the company’s stock after buying an additional 92,390 shares during the quarter. JPMorgan Chase & Co.’s holdings in Vera Therapeutics were worth $9,367,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Vera Therapeutics by 14.3% during the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock valued at $124,737,000 after buying an additional 369,387 shares during the last quarter. Geode Capital Management LLC boosted its position in Vera Therapeutics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock valued at $44,415,000 after purchasing an additional 20,223 shares during the period. Jennison Associates LLC grew its stake in Vera Therapeutics by 82.0% during the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after buying an additional 366,763 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Vera Therapeutics by 19.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 430,665 shares of the company’s stock worth $18,213,000 after buying an additional 68,860 shares during the period. Finally, American Century Companies Inc. lifted its position in Vera Therapeutics by 11.0% in the 4th quarter. American Century Companies Inc. now owns 428,940 shares of the company’s stock valued at $18,140,000 after purchasing an additional 42,526 shares during the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective for the company. Wolfe Research began coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target for the company. JPMorgan Chase & Co. decreased their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Finally, Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $64.67.

Vera Therapeutics Trading Down 4.1 %

Shares of NASDAQ VERA opened at $21.50 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The business has a 50 day simple moving average of $27.25 and a 200 day simple moving average of $37.06. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -8.24 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11. On average, research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.